Acute Kidney Injury Clinical Trials in Birmingham, Alabama

6 studies are recruiting for acute kidney injury in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

   This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) when compared to C…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama Birmingham Hospital, Birmingham, Alabama

   Locations

   36 in total

   Run by

   SeaStar Medical

   See if you can join NCT05758077 on ClinicalTrials.gov

2. A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial

   The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free d…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   9 in total

   Run by

   University of Pittsburgh

   See if you can join NCT05805709 on ClinicalTrials.gov

3. QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

   QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. The purpose of this surveillance registry is to prospectively collect safety data among all patients…

   Stage

   Not phased

   Ages

   Up to 22

   Site

   Children's of Alabama, Birmingham, Alabama

   Locations

   15 in total

   Run by

   SeaStar Medical

   See if you can join NCT06517810 on ClinicalTrials.gov

4. Kidney Function in People With Cystic Fibrosis in the Era of HEMT

   The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect kidney damage early before it becomes permanent. The study will compare these markers in people with…

   Stage

   Not phased

   Ages

   7 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   3 in total

   Run by

   University of Virginia

   See if you can join NCT06595420 on ClinicalTrials.gov

5. Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

   This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   3 in total

   Run by

   Hope Biosciences LLC

   See if you can join NCT06654193 on ClinicalTrials.gov

6. The Biosonographic Index

   In this exploratory study we explore the use of Shear Wave Elastography to differentiate between Acute Kidney Injury after vascular surgery and among the healthy population.

   Stage

   Not phased

   Ages

   19 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT04144894 on ClinicalTrials.gov